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Abstract 
Engineering and functionalizing magnetic nanoparticles have been an area of the extensive 
research and development in the biomedical and nanomedicine fields. Because their bio-
compatibility and toxicity are well investigated and better understood, magnetic nanoparti-
cles, especially iron oxide nanoparticles, are better suited materials as contrast agents for 
magnetic resonance imaging (MRI) and for image-directed delivery of therapeutics. Given 
tunable magnetic properties and various surface chemistries from the coating materials, most 
applications of engineered magnetic nanoparticles take advantages of their superb MRI con-
trast enhancing capability as well as surface functionalities. It has been found that MRI contrast 
enhancement by magnetic nanoparticles is highly dependent on the composition, size and 
surface properties as well as the degree of aggregation of the nanoparticles. Therefore, un-
derstanding the relationships between these intrinsic parameters and the relaxivities that 
contribute to MRI contrast can lead to establishing essential guidance that may direct the 
design of engineered magnetic nanoparticles for theranostics applications. On the other hand, 
new contrast mechanism and imaging strategy can be developed based on the novel proper-
ties of engineered magnetic nanoparticles. This review will focus on discussing the recent 
findings on some chemical and physical properties of engineered magnetic nanoparticles af-
fecting the relaxivities as well as the impact on MRI contrast. Furthermore, MRI methods for 
imaging magnetic nanoparticles including several newly developed MRI approaches aiming at 
improving the detection and quantification of the engineered magnetic nanoparticles are 
described. 
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1. Introduction 
In recent decades engineered magnetic nanopar-
ticles and related nanoconstructs have attracted ex-
tensive research and development in the field of na-
nomedicine.[1-8]  Because their biocompatibility and 
toxicity are extensively investigated and better un-
derstood, magnetic nanoparticles, especially iron ox-
ide nanoparticles (IONPs) composed of maghemite or 
magnetite nanocrystals, are proper choices for various 
in vivo biomedical applications. Among them, mag-
netic resonance imaging (MRI) contrast enhancement 
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for molecular imaging takes advantage of superb and 
tunable magnetic properties of engineered magnetic 
nanoparticles, while a range of surface chemistry of-
fered by nanoparticles provides multifunctional ca-
pabilities for image-directed drug delivery. In parallel 
with the fast growing research in nanotechnology and 
nanomedicine, the continuous advance of MRI tech-
nology and the rapid expansion of MRI applications 
in the clinical environment further promote the re-
search in this area.  
It is well known that magnetic nanoparticles, 
distributed in a magnetic field, create extremely large 
microscopic field gradients. These microscopic field 
gradients cause substantial diphase and shortening of 
longitudinal  relaxation time (T1) and transverse re-
laxation time (T2 and T2*) of nearby nuclei, e.g., proton 
in the case of most MRI applications.[9, 10] The mag-
nitudes of MRI contrast enhancement over clinically 
approved  conventional gadolinium chelate contrast 
agents combined with functionalities of biomarker 
specific targeting enable the early detection of dis-
eases at the molecular and cellular levels with engi-
neered magnetic nanoparticles.[4, 6, 11, 12] While the 
effort in developing new engineered magnetic nano-
particles and constructs with new chemistry, synthe-
sis, and functionalization approaches continues to 
grow, the importance of specific material designs and 
proper selection of imaging methods have been in-
creasingly recognized. Earlier investigations have 
shown that the MRI contrast enhancement by mag-
netic nanoparticles is highly related to their composi-
tion, size, surface properties, and the degree of ag-
gregation in the biological environment.[13-15] 
Therefore, understanding the relationships between 
these intrinsic parameters and relaxivities of nuclei 
under influence of magnetic nanoparticles can pro-
vide critical information for predicting the properties 
of engineered magnetic nanoparticles and enhancing 
their performance in the MRI based theranostic ap-
plications. On the other hand, new contrast mecha-
nisms and imaging strategies can be applied based on 
the novel properties of engineered magnetic nano-
particles. The most common MRI sequences, such as 
the spin echo (SE) or fast spin echo (FSE) imaging and 
gradient echo (GRE), have been widely used for im-
aging of magnetic nanoparticles due to their common 
availabilities on commercial MRI scanners. In order to 
minimize the artificial effect of contrast agents and 
provide a promising tool to quantify the amount of 
imaging probe and drug delivery vehicles in specific 
sites, some special MRI methods, such as 
off-resonance saturation (ORS) imaging and ultra-
short echo time (UTE) imaging, have been developed 
recently to take maximum advantage of engineered 
magnetic nanoparticles.[16-19]  
This review will focus on discussing recent pro-
gresses made in understanding intrinsic factors that 
affect the relaxivity of engineered magnetic nanopar-
ticles as well as the impact on MRI contrast. Further-
more, emerging new MRI techniques specifically de-
veloped for utilizations of magnetic nanoparticles as 
imaging probes and imaging detectable drug delivery 
carriers are described with a special focus on imaging 
of magnetic iron oxide nanoparticles (IONPs).  
2. Engineered Magnetic Nanoparticles for 
Targeted Molecular Imaging by MRI and 
Image-Guided Delivery of Therapeutics  
 Several classes of magnetic iron oxide nanopar-
ticles, also known as superparamagnetic IONPs 
(SPIO) and ultrasmall SPIO (USPIO) developed in 
1980s, has been approved by FDA (e.g., Feridex) for 
clinical applications with capabilities of traditional 
“blood pool” agents.[20, 21] The important properties 
of cell phagocytosis of magnetic nanoparticles has 
expanded the applications of contrast enhanced MRI 
beyond the vascular and tissue morphology imaging, 
enabling many novel applications of magnetic IONPs 
for MRI diagnosis of liver diseases, cancer metastasis 
to lymph nodes, and in vivo tracking of implanted cell 
and grafts with MRI.[21-26] However, the specificities 
of these dextran coated magnetic nanoparticles in 
disease diagnosis are limited. The magnitude of con-
trast effects also need to be improved for high sensi-
tivity to the minimal changes in the disease and for 
biomarker specific detection. Therefore, the function-
alized and engineered magnetic nanoparticles are 
developed to meet the increasing interests for 
non-invasive in vivo imaging of molecular and cellu-
lar activities that target a disease.  
To gain the specificity and reduce the side effect 
and toxicity, biomarker targeted functional proteins 
or  peptide  fragments,  such  as  RGD  targeting  αvβ3 
integrin,  HER2/neu antibody, urokinase type plas-
minogen activator (uPA) amino-terminal fragment 
(ATF), and single chain anti-epidermal growth factor 
receptor (EGFR) antibody were conjugated on the 
surface of magnetic nanoparticles, rendering the na-
noprobes being recognized and internalized by tumor 
cells over expressing the specific receptor.[15, 27-30] 
For example, Yang and co-workers developed a novel 
cell surface receptor-targeted MRI nanoprobe by us-
ing a recombinant peptide ATF of uPA conjugated to 
magnetic iron oxide (ATF-IO) nanoparticles to target 
uPA receptor (uPAR).[27]  
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Figure 1. (a) Illustration of Cy5.5-ATF-IO nanoparticles; (b) dual modality imaging (T2-weighted MRI (left two) and NIRF 
imaging (right)) of subcutaneous 4T1 mouse mammary tumor using Cy5.5-ATF-IO nanoparticles (bottom), no contrast 
change or optical signal is detected in the mouse that received nontargeted iron oxide nanoparticles (top). Adapted with 
permission from the reference [27]. 
 
 
ATF-IO nanoparticles can bind specifically to 
breast cancer cells expressing uPAR followed by cel-
lular internalization through receptor mediated en-
docytosis. This leads to prolonged and enhanced MRI 
contrast in subcutaneous and intraperitoneal mam-
mary tumors in T2 weighted MRI (Figure 1) after in-
travenous administration of ATF-IO nanoparticles 
into tumor  bearing mice. Furthermore, the receptor 
targeted MRI can be confirmed by optical by 
near-infrared fluorescence (NIRF) fluorescence im-
aging in mouse tumor models by co-labeling ATF-IO 
nanoparticles with the NIRF dye molecule, Cy5.5. 
This study and the developed uPAR-targeted ATF-IO 
nanoparticles demonstrated capabilities of function-
alized magnetic nanoparticles and showed a potential 
to improve the specificity of the detection of human 
cancer by receptor targeted molecular MRI with 
magnetic nanoparticle probes. More importantly, re-
searchers recognized the importance of the size effect 
on the relaxivity of the magnetic nanoparticle based 
MRI contrast. Unlike the earlier studies that used size 
variable SPIO made mostly with co-precipitation 
methods in the aqueous medium, ATF-IONPs de-
veloped in this study were consisted of size uni-
formed IONPs (i.e., core size of 10 nm measured by 
TEM) engineered by using the heat-deposition ap-
proach with hydrophobic medium.  
Because one of the major limitations of MRI is its 
relative low sensitivity, the strategies of combining 
MRI with other highly sensitive, but less anatomically 
informative imaging modalities such as positron 
emission tomography (PET) and NIRF imaging, are 
extensively investigated. The complementary 
strengths from different imaging methods can be re-
alized by using engineered magnetic nanoparticles via 
surface modifications and functionalizations. In order 
to combine optical or nuclear with MR for multimodal 
imaging, optical dyes and radio-isotope labeled tracer 
molecules are conjugated onto the moiety of magnetic 
nanoparticles.[31-33] Xie et al. demonstrated the mul-
tifunctionalizations of magnetic nanoparticles via 
dopamine-human serum albumin (HSA) 
procedure.[32]  After exchanging the existing oleic 
acid/oleic  amine, the dopamine modified magnetic 
nanoparticles can be easily encapsulated in HSA 
molecules for further functionalizing. In addition to 
MRI contrast enhancement from the core of the iron 
oxide nanoparticle, the covalent binding and absorp-
tion of 64Cu-DOTA and Cy5.5 provide PET/NIRF 
imaging capabilities. The application of multimodal-
ity MRI/PET/NIRF imaging using this novel probe 
was demonstrated in the U87MG glioma tumor model 
bearing mice. Due to the prolonged circulation time, 
the multifunctional HSA-IO nanoparticles specifically 
accumulated in the tumor site through passively tar-
geting based on the tumor growth associated en-
hanced permeability and retention (EPR) effect. His-
tological examinations and analyses showed that the 
nanoconstructs were distributed intra-vascularly at 
the tumor section and not related to the uptake of 
macrophages.  
As an expansion from the molecular imaging for 
MRI based diagnosis, engineered magnetic nanopar-
ticles have been also developed for the MRI-guided 
delivery of therapeutic agents. For example chemo-
therapeutic drug noscapine (Nos) was attached on the 
human ATF (hATF) peptide conjugated IONPs to 
target uPAR expressed prostate cancer, so that the Theranostics 2012, 2(1) 
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MRI contrast generated from IONPs can be used to 
follow Nos-hATF-IO nanoparticles for MRI-directed 
prostate cancer therapy.[34] The drug carrying uPAR 
targeting magnetic nanoparticles showed specific 
binding to uPAR expressing PC-3 cells. While these 
Nos-hATF-IO nanoparticles with drug molecules 
embedded in the hydrophobic coating layers of 
IONPs demonstrated a ~6-fold improvement in drug 
efficacy, compared to free drug, they also retained the 
MRI contrast effect from the IONPs cores.  Besides 
small drug molecules, some specific antibodies or 
small interfering RNA (siRNA) which can inhibit the 
tumor growth have been also conjugated onto the 
magnetic nanoparticles for MRI-guided therapies. 
Hadjipanayis et al. crosslinked EGFRvIII antibodies to 
IONPs functionalized with carboxyl groups through 
the EDC/NHS reaction.[35]  Significant decrease in 
glioblastoma cells survival was observed after the 
treatment by EGFRvIII-IONPs. MRI-guide convec-
tion-enhanced delivery of EGFRvIII-IONPs increased 
the survival of animals bearing glioblastoma xeno-
grafts.  
Since most functionalities assembled by mag-
netic nanoparticles are accomplished by the surface 
modifications, the chemical and physical properties of 
nanoparticle surface as well as surface coating mate-
rials have considerable effects on the function and 
ability of MRI contrast enhancement of the nanopar-
ticle core. The alterations of MRI contrast due to the 
surface modifications and functionalization as well as 
novel features of coating materials may play roles in 
applications of MRI methods in detecting and quan-
titatively monitor nanodrug bioavailability in the 
tumor tissues in vivo.  
3. Formulation of Engineered Magnetic Na-
noparticles for High Relaxivities and MRI 
Contrast 
The longitudinal and transverse relaxivities, Ri 
(i=1, 2), defined as the relaxation rate per unit con-
centration (e.g., millimole per liter) of magnetic ions, 
reflects the efficiency of contrast enhancement by the 
magnetic nanoparticles as MRI contrast agents. In 
general, the relaxivities are determined, but not lim-
ited, by three key aspects of the magnetic nanoparti-
cles: (i) chemical composition, (ii) size of the particle 
or construct and the degree of their aggregation, and 
(iii) surface properties that can be manipulated by the 
modification and functionalization. It is also recog-
nized that the shape of the nanoparticles can affect the 
relaxivities and contrast enhancement. However these 
shaped particles typically have increased sizes, which 
may limit their in vivo applications. Nevertheless, 
these novel magnetic nanomaterials are increasingly 
attractive and currently under investigation for their 
applications in MRI and image-directed drug deliv-
ery.  
According to Koening-Keller model, the longi-
tudinal or transverse relaxivity Ri can be expressed as 
following:[36]  
        …( 1) 
Where a is a constant, dNP is the diameter of the na-
noparticle, D is the diffusion coefficient of water, μ is 
the  magnetic  moment  of  the  nanoparticles,  γ  is  the 
gyromagnetic ratio of the water proton, CNP  is the 
concentration of the nanoparticles, and J(ω,τD) is the 
spectral density function. As the longitudinal 
(spin-lattice) relaxation T1  contrast agents affect the 
relaxation of water proton through direct energy ex-
change between water and paramagnetic ions, the 
magnetic moment μ is directly related to the unpaired 
electrons. While for the T2 contrast agents in form of 
nanocrystals, the magnetic moment μ is responsible 
on the unpaired electrons as well as the electron in-
teractions in the crystal structure. 
3.1 Composition Effect on MRI Contrast 
The composition of magnetic nanoparticles can 
significantly affect the contrast enhancing capability 
of nanoparticles because it dominates the magnetic 
moment at the atomic level. For instance, the magnetic 
moments of the iron oxide nanoparticles, mostly used 
nanoparticulate T2 weighted MRI contrast agents, can 
be changed by incorporating other metal ions into the 
iron oxide. Cheon and coworkers have demonstrated 
that ferrites ((Fe3+)Td(M2+Fe3+)OhO4, M=Mn, Fe, Co, Ni) 
with different cations doped at the octahedral (Oh) 
sites exhibit different relaxivities according to their 
different mass magnetization. The MnFe2O4 nanopar-
ticles have the highest magnetic moment per unit al-
lowing them to exhibit the highest relaxivity at 358 
mM-1s-1  at 1.5 T among these ferrites.[8]  With Zn2+ 
dopants in tetrahedral (Td) sites leads to even higher 
magnetization value, resulting in R2 relaxivity in val-
ue of 860 mM-1s-1 at 4.7 T.[37] Other efforts on inves-
tigating the compositions of contrast agents were 
made specifically for shortening the longitudinal T1 
relaxation time (e.g. Gd2O3, GdF3, MnO). The selec-
tions of these metals are mainly based on Gd3+  or 
Mn2+ due to their large number of unpaired electrons. 
This is believed to facilitate the relaxation of protons 
through the interaction between the magnetic ions on 
the surface of the particles and the water protons in 
the media. Comparing to iron oxide, Gd3+  or 
Mn2+-based nanoparticles have relatively stronger 
22 1
( , )     ( 1,2) i NP D m
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a
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paramagnetic property (large R1, i.e., 1/T1) and negli-
gible magnetic anisotropy (small R2). For example, the 
R2/R1 value for PEG-Gd2O3 contrast agents is around 
1.0 while the R2/R1  value of commercial negative 
contrast agents, iron oxide nanoparticles such as 
Feridex, is around 10.0.[14, 38] Besides metal oxides, 
metal, and metal alloy nanoparticles are tentatively 
considered as novel particulate contrast agents. This is 
due to their extreme high saturation magnetism 
compared with oxides although their stability and 
potential toxicity in biomedical applications need to 
be addressed. Metallic Fe nanoparticles prepared by 
Hacliipanayis et al. have superb magnetism compared 
to iron oxide nanoparticles. The characterization of 
the MRI contrast effect suggested that the pure Fe 
nanoparticles are powerful contrast agents because of 
the much higher relaxivities (129 mM-1s-1) of pure Fe 
nanoparticles that were measured at 1.5 T, compared 
to IONPs with a comparable size.[39]  Dai and 
co-workers have reported metallic alloy nanoparticles 
for MRI contrast enhancement. They synthesized 
FeCo/single-graphitic-shell nanocrystals and tested 
their magnetic properties as MR contrast agents. High 
relaxivity of FeCo nanoparticles was detected at 1.5 T 
(R1=70 mM−1s−1, R2=644 mM−1s−1 for 7 nm FeCo na-
noparticles), and FeCo has high Ms (215 emu g−1).[38] 
FePt nanoparticles also exhibit high R2  relaxivity 
(122.6 mM−1s−1 for 4 nm FePt nanoparticles at 0.5 T) 
which are superior to T2 contrast agents.[40]  
3.2 Size Effect on MRI Contrast 
The dependence of relaxation rates on the parti-
cle size has been widely studied both theoretically 
and experimentally. Generally the accelerated di-
phase, often described by the R2* in magnetically in-
homogeneous environment induced by magnetic 
nanoparticles, is predicted into two different regimes. 
For the relatively small nanoparticles, proton diffu-
sion between particles is much faster than the reso-
nance frequency shift. This resulted in the relative 
independence of T2 on echo time. The values for R2 
and R2*are predicted to be identical. This process is 
called “motional averaging regime” (MAR) first in-
troduced by Brooks.[41] In this regime, the transverse 
relaxivity R2  increases with increasing particle size. 
However for the larger particles, proton diffusion is 
not the dominant factor for signal decay, as the in-
duced surrounding perturbing field is stronger. 
Therefore, the relaxation rate 1/T2  becomes inde-
pendent on diffusion, and will not increase with the 
increasing particle size. Thus, the value for R2 is usu-
ally smaller than R2*. This process is called “static 
dephasing regime” (SDR) which was first introduced 
by Yablonskiy and Haacke.[42] Usually the small sin-
gle core magnetic nanoparticles developed by many 
research groups and commonly used for MRI appli-
cations in vivo are in the MAR. This is where larger 
magnetic nanoparticles possess a larger magnetiza-
tion and exhibit higher R2 relaxivity. 
As described in the Eq. 1, transverse relaxivity R2 
is proportional to the magnetic moment. Although 
magnetism is an intrinsic property of bulk materials, 
the magnetic properties of nanoparticles are strongly 
dependent on their size, shape, and surface proper-
ties. It has been well demonstrated that the saturation 
magnetization Ms increases with the particle size. A 
linear relationship is predicted between Ms1/3  and 
d-1.[8, 13, 14, 43] Therefore, the capability of MRI sig-
nal enhancement by nanoparticles correlates directly 
with the particle size. For example, Cheon and 
co-workers systematically studied the relationships 
among size, magnetism, and relaxivity using size 
uniformed iron oxide nanoparticles. They found that 
the transverse relaxivity coefficient (R2) value of the 
iron oxide nanoparticles gradually increases from 78 
mM-1s-1 to 106, 130, and to 218 mM-1s-1 at 1.5 T as the 
particle size increases from 4 nm to 6, 9, and 12 nm 
respectively.[44]  Many other research groups have 
also reported on the similar size effect of relaxation 
rates.[8, 38, 45, 46] However, the R2 relaxivity is pre-
dicted to approach a plateau as the particle size con-
tinues increasing according to the SDR theory.[47] In 
the case of polyvinylpyrrolidone (PVP) coated IONPs, 
R2  values increased from 173.37 mM-1s-1  to 203.86, 
239.98, and 248.89 mM-1s-1 at 7 T, when the particle 
size arise from 8 nm to 23, 37, 65 nm, respectively. 
However, it has been reported that the size effect be-
came less significant for the single core IONPs above 
50 nm.[31] 
Another approach for enhancing magnetic 
properties for high MRI contrast effect is to fabricate 
magnetic nanoclusters comprised of small magnetic 
nanoparticles, as a result, increasing effective  mag-
netic size. Gao and co-workers developed a type of 
nanoclusters with polymeric micelles encapsulating 4 
nm iron oxide nanoparticles. They demonstrated the 
dramatic increase of the R2 relaxivity (169 Fe mM-1s-1 
increased from 25.1 Fe mM-1s-1 at 1.5 T), thus substan-
tially improving the detection sensitivity (at nano-
molar concentration) of targeted tissues.[48] Berret et 
al. investigated the relaxation behaviors of 6.3 nm 
IONPs and their nanoclusters. It is found that the R2 
relaxivity value is noticeably increased with the size 
of the magnetic clusters. Compared to 39 mM-1s-1 of 
bare single IONPs, the transverse relaxivity R2 of the 
IONPs clusters change from 74 mM-1s-1 to 162 mM-1s-1 
at 0.47 T as the cluster size increases from 70 nm to 170 
nm.[49]  After enwrapped with amphiphilic diblock Theranostics 2012, 2(1) 
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copolymer PEO-b-PγMPS  developed  by  Chen  et  al, 
13-nm IONPs formed clusters with an averaged core 
size of 50 nm, resulting much higher magnetization 
saturation and subsequently higher transverse relax-
ivity R2 value as shown in Figure 2.[50] The investi-
gation by Weller and co-workers suggested that ho-
mogeneously dispersed nanoparticles satisfy the 
MAR theory while the clusters embedded in lipid 
micelles is in agreement with the SDR theory with 
capability of greatly enhancing contrast in 
T2*-weighted images.[46]  
For the particulate T1 contrast agents, the para-
magnetic ions incorporated on the surface of nano-
particles are responsible for the shortening longitu-
dinal relaxation time T1. As a result, the relaxivity R1 is 
more dependent on the total surface area of the na-
noparticles than on the size of the nanoparticles. Re-
cently, Hyeon and co-workers developed MnO na-
noparticles with T1 contrast enhancement and tested 
in MR imaging of brain, liver, and kidney.[51] They 
found that the relaxivity R1  decreases with the in-
creasing particle size. The R1 value changes from 0.37 
mM-1s-1 to 0.18, 0.13 0.12 mM-1s-1 at 3.0 T, as the parti-
cle size increases from 7 nm to 15, 20, 25 nm. To in-
crease surface-to-volume ratio, they etched MnO na-
noparticles into hollow structures, where more active 
Mn2+ are exposed to water.[52] As a result, the hollow 
MnO nanoparticles exhibited much higher R1 value 
(1.42 mM-1s-1) compared to the solid ones (0.21 
mM-1s-1). With the hollow core-shell configuration, 
such nanoconstruct could be applied as a drug deliv-
ery system with effective MRI contrast enhancement 
for MRI monitoring drug delivery. 
 
 
 
 
Figure 2 . (a) Schematic illustration of the stabilization of nanoparticles with a single core or a multi-core in water using the 
amphiphilic diblock copolymer PEO-b-PγMPS. (b) Plots of the linear correlations of transverse relaxation rates (1/T2, s
–1) of 
PEO-b-PγMPS-coated monodisperse single core (□) and clustered (○) IONPs against the iron concentration (mmol/L), 
allowing the transverse relaxivities at 3 Tesla of each nanoparticle formation to be derived from the slopes of the plots. (c) 
Magnetization of monodisperse single core and clustered IONPs as a function of the applied magnetic field. Adapted with 
permission from ref [50]. 
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3.3 Nanoparticle Surface Properties Effect on 
MRI Contrast 
MRI contrast comes from the signal difference 
between water molecules residing in different envi-
ronments that are under the effect of magnetic nano-
particles. Because the interactions between water and 
the magnetic nanoparticles occur primarily on the 
surface of the nanoparticles, surface properties of 
magnetic nanoparticles play important roles in their 
magnetic properties and the efficiency of MRI contrast 
enhancement. As most biocompatible magnetic na-
noparticles developed for in vivo applications need to 
be stabilized and functionalized with coating materi-
als, the coating moieties can affect the relaxation of 
water molecules in various forms, such as diffusion, 
hydration and hydrogen binding. The early investi-
gation carried at by Duan et al suggested that hy-
drophilic surface coating contributes greatly to the 
resulted MRI contrast effect.[45]  Their study exam-
ined the proton relaxivities of iron oxide nanocrystals 
coated by copolymers with different levels of hydro-
philicity including: poly(maleic acid) and octadecene 
(PMO), poly(ethylene glycol) grated polyethyl-
enimine (PEG-g-PEI), and hyperbranched polyethyl-
enimine (PEI). It was found that proton relaxivities of 
those IONPs depend on the surface hydrophilicity 
and coating thickness in addition to the coordination 
chemistry of inner capping ligands and the particle 
size. Directly exchange between the multivalent lig-
ands (e.g. PEI and PEG-g-PEI) with the original hy-
drophobic surface ligand (e.g. oleic acid) facilitates the 
accessibility of water to the magnetic core. This leads 
to the rapid exchange and diffusion of water mole-
cules between the bulk phase and the adjacent layer 
surrounding the particle surface. 10 nm IONPs coated 
with high hydrophilic PEI polymer showed the high-
est R2 and the largest signal drop in T2 weighted fast 
spin-echo imaging as shown in Figure 3.  
 
 
Figure 3. (a-d) Organic polymers for solubilizing hydrophobic iron oxide nanocrystals and schematic structures of poly-
mer-coated iron oxide nanocrystals: (a) oleic acid; (b) copolymer of poly(maleic acid) and octadecene (PMO); (c) 
poly(ethylene glycol) grated polyethylenimine (PEG-g-PEI), (d) hyperbranched polyethylenimine (PEI). (e) Comparison of 
traverse relaxation signal intensities (T2) for pure water, Gd-DTPA (a gadolinium complex), and polymer-coated iron oxide 
nanoparticles as a function of echo delay time. (f) T2-weighted contrasts and color coded R2 maps for iron oxide nanocrystals 
(10 nm core size) with different polymer coatings. Adapted with permission from ref [45]. 
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This was almost three times higher than that of 
PMO coated nanoparticles, which have the lowest 
hydrophilicity. Meanwhile, the capping ligands that 
strongly bind to surface iron (e.g. oleic acid) largely 
influence intrinsic surface spin disorders. This par-
tially offset the size effect arisen from the larger sur-
face area to volume ratios. The proton relaxivity of 30 
nm IONPs coated with oleic acid and PMO is 2.6 
times that of 10 nm particles, while the increase is less 
than 40% for that capped with PEI.  
The thickness of surface coating materials also 
contributed to the relaxivity and contrast effect of the 
magnetic nanoparticles. Tong et al systematically 
modified the core size and polyethylene glycol (PEG) 
coating of SPIOs for the maximal R2  relaxivity 
per-particle.[53]  Using 1, 2-distearoyl-sn-glycero-3- 
phosphoethanolamine-N-[methoxy (polyethylene 
glycol)] copolymer (DSPE-mPEG), they were able to 
control the coating thickness by varying the size of 
PEG from 500 Da up to 5000 Da. Generally, the 
measured T2  relaxation time increases as molecular 
weight of PEG increases, although the effect of the 
PEG thickness also interplays with the particle core 
size. At the optimal condition using 1000 Da of PEG 
coating 14 nm core iron oxide nanoparticles, the R2 
relaxivity of PEG coated SPIO reached a value of 385 
s−1mM−1 at 7 T, more than 2.5 folds higher than that 
coated with PEG 5000 Da. The significant thinner 
coating thickness of PEG 1000 (hydrodynamic size of 
28.4 nm for 14 nm core) is considered to be the major 
factor of the improved relaxivity.  
Weller and co-workers investigated the relaxivi-
ties of MnFe2O4 nanoparticles modified through lig-
and exchange through additional polymeric coating 
and lipid micellar embedding.[46] The transverse re-
laxivity, R2* is greatly higher for the micellar system 
compared to the polymer-coated particles transferred 
from same-sized nanoparticles. One explanation for 
the observed high R2  is that the core cluster inside 
lipid micelles has a larger overall size than the single 
dispersed polymer-coated nanoparticles. In addition 
to the discussed composition concern, the surface 
properties are also important for the responsibility of 
contrast enhancement. Lipid molecules influence the 
diffusion of water inside the micelles and in their 
surroundings. Furthermore, the dephasing proton 
spins of the lipid molecules also contribute to the 
signal reduction due to the high viscosity of these 
molecules.  
4. Novel MRI Methods for Improving the 
Imaging Contrast, Sensitivity, Detectability 
and Quantification of Magnetic Nanoparti-
cles 
Utilization of contrast agents in MRI leads to 
hypointense/hyperintense signals in MR images, 
generating so-called “negative contrast”/“positive 
contrast”. Because magnetic nanoparticles provide 
various contrast enhancement options, MRI methods 
and new imaging sequences can be developed and 
applied based on different contrast mechanisms to 
improve the detection of engineered magnetic nano-
particle probes. More importantly probes and drug 
delivery vehicles can be quantified in vivo using MRI. 
With a better understanding of MRI contrast mecha-
nisms and properties of contrast materials, the design 
and preparation of engineered magnetic nanoparticles 
therefore can be specifically “tailored” to take ad-
vantage of the MRI methods for the intended imaging 
applications.  
4.1. Conventional MRI Sequences and Methods 
for Imaging Magnetic Nanoparticles 
Unlike the conventional small molecule gado-
linium chelate contrast agents, magnetic nanoparticle 
based on MRI probe has strong field strength de-
pendency  due to the superparamagnetic nature of 
magnetic nanoparticles. In a detailed report, Rohrer et 
al studied and compared various commercially 
available contrast agents for MRI in terms of their R1 
and R2 relaxivities at magnetic field strengths ranging 
from 0.47T to 4.7T.[54]  Their results showed that 
compared to the Gd-based chelates, contrast agents 
based on superparamagnetic iron oxide, e.g. Feridex 
and  Resovist, exhibited significant dependencies  of 
relaxivities on the field strengths. Therefore, in pre-
clinical animal imaging research, magnetic nanopar-
ticles offer the best sensitivity as high field MRI in-
strumentation is typically used. Experiments are often 
done at the field strengths ranging from 4.7 T to 11.7 T 
for MRI and MR microscopy imaging with different 
animal models.[55-57]  
Most engineered magnetic nanoparticles are 
known as excellent T2 and T2* contrast agents. Mag-
netic nanoparticles, in a magnetic field, create ex-
tremely large microscopic field gradients to diphase 
nearby protons, and exhibit superb ability in short-
ening transverse relaxation times T2 and T2*.[10, 58] 
Therefore,  the  most commonly used  imaging se-
quences for detecting magnetic nanoparticles are T2 
and T2*  weighted  sequences.[23, 59-62]  Spin-echo 
based T2 weighted imaging provides great anatomic 
details, and it is insensitive to the susceptibility arti-
facts because of the property of spin echo readout. On 
gradient-recalled echo (GRE) images, where T2* ef-
fects dominate, an even stronger decrease in signal 
intensity of target organs is induced. GRE imaging 
generates more hypointense contrast in T2* weighted Theranostics 2012, 2(1) 
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images compared to T2  weighted  SE  images.[60] 
However, gradient-echo based T2* weighted imaging 
is more vulnerable to the susceptibility artifacts rising 
from the tissue-air interface and iron depositions or 
other local inhomogeneities in some organs and dis-
eased areas, e.g., bone marrow and lung.  
Imaging sequences used for detecting magnetic 
nanoparticles are mainly categorized as T2 weighted 
imaging, T2 relaxometry, and T2* weighted imaging. 
Although both T2 and T2* weighted imaging approach 
offer high sensitivity for detecting magnetic nanopar-
ticles, the main drawback of the negative contrast is 
its poor contrast when used to study areas that have 
low background signals. Another drawback is  that 
they are interfered by high magnetic inhomogeneity 
or susceptibility effect, which also results in the in-
trinsic tissue signal void. T2 and T2* weighted imaging 
methods are also vulnerable to the “blooming” arti-
facts and partial volume effects making accurate lo-
calization and quantitative imaging difficult.[59, 63] 
Furthermore, higher magnetic susceptibility and 
stronger T2 and T2* effect from large sized magnetic 
nanoparticles may not be translated to better negative 
contrast in T2 and T2* weighted imaging. The contrast 
may not improve further as the level of signal de-
crease cannot get beyond voiding the signal from its 
original level.[64]  To overcome these limitations of 
negative contrast of conventional MRI methods, sig-
nificant efforts have been made in developing alter-
native imaging methods that are capable of enhancing 
the signal or generating bright and positive contrast to 
improve the detection of magnetic nanoparticles.  
4.2. Turning the Contrast Opposite – “Bright 
Imaging” of Magnetic Nanoparticles 
One attractive approach for generating positive 
contrast is the off-resonance excitation methods. 
Cunningham et al.[65]  and  Balchandani  et al.[66] 
proposed to visualize magnetic nanoparticle affected 
protons by selectively exciting the off-resonance spins 
surrounding  the labeled cells  to  generate positive 
contrast.  In addition, inversion-recovery with 
on-resonant water suppression (IRON) may be used 
in conjunction with the spectrally selective RF 
pulses.[67] Alternatively, fast low-angle positive con-
trast steady-state free precession imaging (FLAPS) is 
able to generate positive contrast from the 
off-resonant spins while suppressing the on-resonant 
spins in a flip-angle-dependent manner. Because the 
background suppression is controllable, 
co-registration of the bright signal as a result of the 
contrast enhancement by the magnetic nanoparticles 
and the anatomic details can be made in the same 
image.[68, 69] 
Alternatively,  Zurkiya et al. reported an 
off-resonance saturation (ORS) method to produce 
positive contrast.[70] In this method, an RF pulse is 
designed to be applied at an off-resonance frequency 
and bulk water protons are imaged with and without 
the presence of the ORS pulse. This method relies on 
diffusion  saturation transfer  to reduce the 
on-resonance MRI signal. This is similar to chemical 
exchange saturation transfer. The positive contrast 
was obtained by taking the ratio or subtraction of the 
images with and without the saturation. Using this 
ORS  approach,  Khemtong  et al  successfully turned 
“ON” the tumor-targeted superparamagnetic 
polymeric micelles (SPPM) in vivo, in contrast to the 
“negative” contrast from the T2* weighted GRE 
imaging (Figure 4).[18]  
Recently  Zhou et al. developed a different ap-
proach to exploit  the positive contrast with a  rela-
tively new technique called sweep imaging with Fou-
rier transformation (SWIFT).[71] SWIFT is based on a 
frequency-swept excitation with virtually simultane-
ous signal acquisition with the radiofrequency excita-
tion. Therefore it is particularly well suited to image 
objects with extremely fast transverse relaxation rates 
such as IONPs.  Unlike the off-resonance excitation 
methods, which generate images that contain signal 
only in  areas that correspond to the locations of 
IONPs and therefore need an extra image acquisition 
to provide background anatomic details, SWIFT ap-
proach  generates IONP-related signal as  positive 
contrast in the imaginary  component of the  image. 
The magnitude image contains all the anatomic de-
tails of the heart (Figure 5).  
Owing to the predominant T2 or T2* effects over 
the usual dipole-dipole  relaxation mechanism that 
affects both T1 and T2, IONPs are usually treated as T2 
or T2* contrast agents. On the other hand, IONPs also 
exhibit  a high  longitudinal  R1  relaxivity  providing 
intrinsic  signal enhancement on T1  weighted 
images.[72, 73]  However,  conventional imaging se-
quences cannot fully take advantage of such strong T1 
weighted contrast effect because of the predominant 
T2 and spin dephase effects of IONPs. Ultrashort echo 
time (UTE) imaging is capable of imaging materials 
with extremely short T2 and very fast signal decay.[74] 
With  very short echo time, typically below 0.1  ms, 
UTE imaging allows for signal acquisition with little 
T2 influence. In a recent study by Zhang et al, UTE 
imaging was applied to generate T1 weighted positive 
contrast enhancement for IONPs with different core 
sizes and concentrations in phantoms (Figure 6).[19]  
The UTE imaging was also demonstrated to 
yield  positive contrast for U87MG human glioblas-
toma cells targeted with an IONPs conjugated with a Theranostics 2012, 2(1) 
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small peptide ligand of arginine-glycine-aspartic acid 
(RGD).  This has a high affinity to the cells overex-
pressing αvβ3 integrin (Figure 7).[19] 
4.3. MRI Quantification of Magnetic Nanoparti-
cles 
Ideally, the amount of IONPs should be quanti-
fied so that longitudinal studies can be performed for 
monitoring the delivery of drug delivery, tracking the 
nanoparticle distributions, and evaluating as well as 
comparing the treatment responses. Quantitative re-
laxometry or mapping of relaxivity values over the 
imaged area  is a common and straightforward ap-
proach. The relaxometry methods usually use the 
magnitude information from multi-echo MR images 
and quantify the concentration of IONPs by fitting the 
relaxation rate of the IONPs within the tissue. By ac-
quiring data with a multi-echo SE sequence and fit-
ting the signal intensities to the exponential T2 decay 
equation, Hogemann et al.  calculated T2  maps of a 
limited library of peptide-nanoparticles conjugates for 
cell  uptake  on 1920  samples of six 384 well plates 
(each contains 16×20 wells). This demonstrated that T2 
mapping  provided  exceedingly accurate measure-
ments and receptor  binding/internalization data as 
validated by radioactive assays.[75]  
 
 
Figure 4. Comparison of ORS and T2* weighted imaging of SPPM nanoprobes (20 μL, 0.25 mg/mL) intratumorally injected 
inside an A549 tumor xenograft in a mouse. (a) ORS and T2* weighted images of the transverse section of a representative 
mouse bearing two tumor xenografts (one for SPPM injection (red dashed circle), the other as SPPM-free control) before 
and after the injection of SPPM. The ∆ORS images were obtained by pixel-by-pixel subtraction of ORS ON images from ORS 
OFF images and overlaid with ORS OFF images. (b) Statistical comparison of CNRs of SPPM-injected versus SPPM-free 
tumors by the ORS and T2* weighted methods. Reprinted with permission from ref [18]. Theranostics 2012, 2(1) 
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Figure 5. (a) In vivo GRE image; (b) ex vivo SWIFT imaginary and (c) magnitude; (d) ex vivo GRE magnitude images obtained 
from a heart receiving 0.5 M IONP-labeled stem cells. Arrows indicate location of cells. (e-g) Prussian blue staining of the 
heart sections at the corresponding level of MR images. Magnified views of the box in (e) and (f) are presented in (f) and (g), 
respectively. Reprinted with permission from ref [71]. 
 
 
 
 
Figure 6. Comparison of T1-weighted UTE and conventional T2-weighted TSE images of IONPs; (a) T1 weighted UTE 
images of selected IONP samples. (b) Conventional T2 weighted TSE images of the same samples. In each image panel, the 
top row is the IONP samples with a core size of 25.4 nm and the bottom row is the IONP samples with a core size of 8.7 
nm, and the concentrations are corresponding to level 1 (left most) to level 5 (right most). UTE images have lower in plane 
resolution (1.1 × 1.1 mm
2 isotropic) than that of T2 weighted TSE images (0.7 × 0.7 mm
2 isotropic). Reprinted with per-
mission from ref [19]. Theranostics 2012, 2(1) 
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Figure 7. (a) Prussian blue staining confirmed the presence of tumor integrin targeted RGD-IONP conjugates in U87MG 
human glioblastoma cells. (b) Comparison of moderately T1 weighted TSE images (top), moderately T2 weighted TSE images 
(middle) and T1 weighted UTE images (bottom) of cell phantoms containing 0, 1, 2, 4 and 8 × 10
6 U87MG glioblastoma cells 
bound with RGD-IONP conjugates. Cells were embedded in 2% agarose gel. Reprinted with permission from ref [19]. 
 
 
Lee et al visualized small tumors implanted in a 
mouse with their ultra-sensitive mag-
netism-engineered iron oxide  (MEIO), and  he  used 
T2/R2  mapping to evaluate  the enhancement and 
sensitivity of their approach.[8] In a recent study, Liu 
et al used T2 mapping to show the over expression of 
ferritin for the demonstration of metalloprotein re-
porter gene-based noninvasive monitoring of em-
bryonic stem cells in vivo.[76] Because T2 relaxometry 
methods applied a ”shot-gun” approach to capture T2 
decay trend with multiple echo times in one scan. It 
has better sensitivity than conventional T2 weighted 
imaging which uses only one echo time that may not 
be an optimal one for maximal contrast. Since the T2 
relaxivity is closely correlated with the concentration 
of the magnetic nanoparticles given specific phys-
ic-chemical properties, the quantification of magnetic 
nanoparticles can be accomplished.  
Alternatively, T2* mapping can be obtained us-
ing multi-echo GRE sequence. Because T2* has a 
greater sensitivity compared T2, T2* mapping is ex-
pected to be more sensitive than T2 mapping. How-
ever, for IONPs with extremely short T2* relaxation 
times (e.g. ≤ 3 ms), the signal decay may be too rapid 
for the regular GRE sequence. In a recent study, Liu et 
al. developed a shifted spin echo (SSE) sequence to 
allow the acquisition of ultrashort T2* 
relaxometry.[77]  Combined with the regular mul-
ti-echo GRE sequence, their approach was able to 
provide  quantification  of  highly concentrated 
iron-labeled cells from direct cell transplantation with 
had extremely short T2* (Figure 8).  
Model-based methods provide alternative ways 
to quantify magnetic nanoparticles. With prior 
knowledge of empirical  physics and mathematics 
models and the MRI data acquired corresponding to 
the model design, the model-based methods quantify 
the concentration of IONPs by fitting the experimental 
MR data in the models. For example, Zurkiya et al 
proposed a simple model for the ORS method in their 
original publication which shed the light of quantify-
ing  magnetic nanoparticles  using the ORS 
method.[70]  In addition, Khemtong  et al further 
reported a theoretical model of ORS contrast and its Theranostics 2012, 2(1) 
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experimental  validation by SPPM with precisely 
controlled structural properties.  A simplified 
mathematical expression was proposed that allowed 
for quantitative approximation of ORS contrast for a 
given SPPM solution with known T1  and T2 
values.[78]  
Very recently, a phase gradient mapping (PGM) 
method, namely finite perturber method, was 
proposed by Langley et al.[79] and Zhao et al.[80] This 
method models magnetic field inhomogeneities by 
approximating regions containing IONPs as 
ensembles of magnetic dipoles, and it  fits the 
magnetic field of the model to the experimental 
magnetic field inhomogeneities identified in the 
acquired phase maps. This method was verified using 
data acquired from in vivo mouse models, and it was 
able to give estimations of the concentration within 
IONP-labeled tumors that were  reasonably close to 
the known concentration.[79] 
Another promising approach to quantify  mag-
netic nanoparticles  arises from the UTE method. In 
the study performed by Zhang et al, increases of the 
signal intensity and positive contrast of IONPs in UTE 
images were found to be correlated to the increases of 
the size and iron concentration of IONPs (Figure 
9).[19] Specifically, for a certain core size of the mag-
netic nanoparticle, excellent linear correlation was 
found between the signal intensity of UTE images and 
the concentration of the magnetic nanoparticle (Fig-
ure 9b). This linear relationship can possibly be used 
as a simple and straightforward model to quantify 
magnetic nanoparticles according to the intensity of 
UTE images after calibration.  
 
 
Figure 8. (a) GRE image of an axial slice of a rat with IONP-labeled flank tumors (yellow arrows); (b) SE image of the same 
slice; (c) Regular T2* map from the multi-echo GRE sequence; (d) SSE ultrashort T2* map; (e) SSE ultrashort T2* map overlaid 
on the regular T2* map; (f) Profile of the yellow line in (e). The dark regions within the tumors in (a) and (c) corresponded 
to highly concentrated IONP-labeled cells. The multi-echo GRE T2* mapping technique failed to detect any signal from the 
center of the tumors (dark circle) but the SSE ultrashort T2* mapping technique adequately characterized the T2* relaxation 
times. The zoomed view in (f) clearly illustrated that T2* values in the tumor center were in the range of 0~2 ms. Reprinted 
with permission from ref [77]. Theranostics 2012, 2(1) 
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Figure 9. Plots of the signal intensity of T1 weighted UTE images of IONP samples with different core sizes (a) and con-
centrations (b) show stronger positive contrast with higher iron concentrations and larger core sizes. Pearson correlation 
coefficients of each plot are indicated in the figure legends. Signal intensity is in arbitrary unit (marked as A.U. in the figures). 
Reprinted with permission from ref [19]. 
 
5. Conclusion 
Much progress has taken place in the theranostic 
applications of engineered magnetic nanoparticles, 
especially in MR imaging technologies and nano-
materials development. As the feasibilities of mag-
netic nanoparticles for molecular imaging and drug 
delivery have been demonstrated by a great number 
of studies in the past decade, MRI guiding and mon-
itoring techniques are desired to improve the disease 
specific diagnosis and efficacy of therapeutics. Con-
tinuous effort and development are expected to be 
focused on further improvement of the sensitivity and 
quantifications of magnetic nanoparticles in vivo for 
theranostics in future.  
The new design and preparation of magnetic 
nanoparticles need to carefully consider the parame-
ters determining the relaxivities of the nanocon-
structs. Sensitive and reliable MRI methods have to be 
established for the quantitative detection of magnetic 
nanoparticles. The new generations of magnetic na-
noparticles will be made not only based on the new 
chemistry and biological applications, but also with 
combined knowledge of contrast mechanisms and 
MRI technologies and capabilities. As new magnetic 
nanoparticles are available for theranostic applica-
tions, it is anticipated that new contrast mechanism 
and MR imaging strategies can be developed based on 
the novel properties of engineered magnetic nano-
particles.  
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